
Dec 31 (Reuters) - Climb Bio Inc CLYM.O:
CLIMB BIO INC - FILES COMPLAINT AGAINST ALUMIS AND ACELYRIN - SEC FILING
CLIMB BIO INC - COMPLAINT RELATING TO A DISPUTE CONCERNING AN ASSET PURCHASE AGREEMENT, DATED AS OF JANUARY 11, 2024
CLIMB BIO INC - COMPLAINT SEEKS DECLARATORY JUDGMENT THAT CO'S BUDOPRUTUG DRUG CANDIDATE IS NOT "PRODUCT" UNDER APA
CLIMB BIO INC - DOES NOT OWE A MILESTONE PAYMENT SOUGHT BY ALUMIS IN CONNECTION WITH ITS DEVELOPMENT OF BUDOPRUTUG
Source text: [ID:n0001193125-25-338318]